Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Byron Padilla"'
Autor:
Shawn G. Kwatra, Saakshi Khattri, Ahmad Z. Amin, Roberto Ranza, Blair Kaplan, Linyu Shi, Byron Padilla, Ahmed M. Soliman, Dennis McGonagle
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 6, Pp 1517-1530 (2024)
Abstract Introduction The presence (vs absence) of enthesitis/dactylitis is associated with greater psoriatic arthritis (PsA) activity and reduced health-related quality of life. Risankizumab, an interleukin 23 antagonist, demonstrated superior treat
Externí odkaz:
https://doaj.org/article/208376fab02442ef8617f079f73a4f2b
Autor:
Andrew Östör, Filip Van den Bosch, Kim Papp, Cecilia Asnal, Ricardo Blanco, Jacob Aelion, Kyle Carter, Vassilis Stakias, Ralph Lippe, Leonidas Drogaris, Ahmed M. Soliman, Michael M. Chen, Byron Padilla, Alan Kivitz
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 3, Pp 633-648 (2024)
Abstract Introduction Long-term therapeutic options providing durable response and tolerability are needed for psoriatic arthritis (PsA). The ongoing KEEPsAKE 2 trial is evaluating risankizumab treatment in patients with active PsA who previously had
Externí odkaz:
https://doaj.org/article/9ce4042ecece4341be994d1a7b7901c4
Autor:
Lars Erik Kristensen, Mauro Keiserman, Kim Papp, Leslie McCasland, Douglas White, Kyle Carter, Ralph Lippe, Huzefa Photowala, Leonidas Drogaris, Ahmed M. Soliman, Michael Chen, Byron Padilla, Frank Behrens
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 3, Pp 617-632 (2024)
Abstract Introduction Patients with psoriatic arthritis (PsA) require treatment providing durable long-term efficacy in different disease domains as well as safety. We present 100-week efficacy and safety results of risankizumab in patients with acti
Externí odkaz:
https://doaj.org/article/d175f505a9724186801cfc38fbee94d1
Autor:
Joseph F. Merola, April Armstrong, Saakshi Khattri, So Yeon Paek, Byron Padilla, Cuiyong Yue, Huzefa Photowala, Blair Kaplan, Lars Erik Kristensen
Publikováno v:
Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
AbstractIn the KEEPsAKE 1 (NCT03675308) and KEEPsAKE 2 (NCT03671148) phase 3 trials, risankizumab demonstrated greater efficacy compared with placebo in patients with active psoriatic arthritis (PsA). This post hoc integrated analysis evaluated achie
Externí odkaz:
https://doaj.org/article/39e61f6277034f2f88e208b5a6fe086b
Autor:
Kurt de Vlam, Alan Kivitz, Andrew J K Ostor, Zailong Wang, Ahmed M Soliman, Ann Eldred, Kim A Papp, Byron Padilla
Publikováno v:
RMD Open, Vol 8, Iss 2 (2022)
Objectives Determine the impact of 24-week risankizumab (RZB) versus placebo (PBO) on patient-reported outcomes (PROs) in patients with psoriatic arthritis (PsA) and inadequate response to one or two biologics (Bio-IR) and/or ≥1 conventional synthe
Externí odkaz:
https://doaj.org/article/838882eaf5b84a6c88601c84524195e0
Publikováno v:
Práctica Familiar Rural, Vol 6, Iss 2 (2021)
Se presenta el caso de un paciente masculino de diecinueve años de edad, que debuta con síndrome constitucional, fiebre prolongada de origen desconocido, signos y síntomas digestivos; con alta sospecha de neoplasia gástrica se decide su hospitali
Externí odkaz:
https://doaj.org/article/bf036b7b5a414002928c808bb063c443
Autor:
Andrew J K Ostor, Ahmed M Soliman, Kim A Papp, Byron Padilla, Zailong Wang, Ann Eldred, Kurt de Vlam, Alan Kivitz
ObjectivesDetermine the impact of 24-week risankizumab (RZB) versus placebo (PBO) on patient-reported outcomes (PROs) in patients with psoriatic arthritis (PsA) and inadequate response to one or two biologics (Bio-IR) and/or ≥1 conventional synthet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5687708e57b1358b109d0f30b6df7210
https://lirias.kuleuven.be/handle/20.500.12942/707334
https://lirias.kuleuven.be/handle/20.500.12942/707334
Autor:
Andrew Östör, Filip Van den Bosch, Kim Papp, Cecilia Asnal, Ricardo Blanco, Jacob Aelion, Wenjing Lu, Zailong Wang, Ahmed M Soliman, Ann Eldred, Byron Padilla, Alan Kivitz
Publikováno v:
RHEUMATOLOGY
Objective PsA is a chronic inflammatory disease in which the skin and joints are affected. In this follow-up analysis, the 52-week efficacy and safety of risankizumab 150 mg in patients with active PsA who had previous inadequate response/intolerance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6495438b10a7affaac59b7f05905eb8d
https://pubmed.ncbi.nlm.nih.gov/36282537
https://pubmed.ncbi.nlm.nih.gov/36282537
Publikováno v:
Dermatology and Therapy
Introduction Although many biologic therapies are effective for clearing skin of patients with psoriasis, some lose effectiveness over time. This phase 2 open-label extension (OLE) trial was designed to investigate the long-term safety and efficacy o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b59a6b772be3b2d4acb29c053354a77d
http://europepmc.org/articles/PMC8018913
http://europepmc.org/articles/PMC8018913
Autor:
Mark G. Lebwohl, Ahmed M. Soliman, Hongbo Yang, Jessie Wang, Kaitlin Hagan, Byron Padilla, Andreas Pinter
Publikováno v:
Dermatology and therapy. 12(2)
Novel therapies have allowed psoriasis patients to achieve high levels of skin clearance and meaningful improvements in health-related quality of life measures; however, duration of these outcomes has not been evaluated. This study aimed to estimate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::674f92db998468f24839850f6ae0dc6f
https://pubmed.ncbi.nlm.nih.gov/34921669
https://pubmed.ncbi.nlm.nih.gov/34921669